Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis. 2020

Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
Hunan Key Laboratory of Oral Health Research & Hunan 3D Printing Engineering Research Center of Oral Care & Hunan Clinical Research Center of Oral Major Diseases and Oral Health Xiangya Stomatological Hospital & Xiangya School of Stomatology, Central South University, Changsha, 410008, Hunan, PR China; Department of Oral Maxillofacial Surgery, Xiangya Stomatological Hospital & School of Stomatology, Central South University, Changsha, Hunan, 410008, PR China. Electronic address: hongzhi.quan@csu.edu.cn.

OBJECTIVE The aim of our study was to investigate the expression of programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) between oral squamous cell carcinoma (OSCC) patients with and without oral submucous fibrosis (OSF), and its correlation with clinic-pathologic features and its prognostic value. METHODS PD-L1 and PD-1 expression was evaluated by immunohistochemical staining, double immunofluorescent staining and real-time PCR, and the correlation of PD-L1/PD-1 expression with clinical outcome was assessed. RESULTS The level of PD-L1 expression was significantly higher in OSCC with OSF than in OSCC without OSF (p = 0.006). Moreover, PD-L1 expression was strongly correlated with lymph node metastasis (p = 0.016), and advanced tumor stage (p = 0.030). Increased PD-L1 expression was positively correlated with the incidence of OSCC with OSF (p = 0.006, p = 0.008, respectively). PD-L1 expression was an independent marker of unfavorable prognosis (p = 0.035, p = 0.048, respectively). High PD-L1 expression had a significantly worse outcome in OSCC patients with OSF (p = 0.014). Double immunofluorescent staining showed that OSCC with OSF were more strongly expressed both PD-L1 and PD-1 than OSCC without OSF. Moreover, the expression of PD-L1 were upregulated in OSCC tissues than normal control (p = 0.0422), and both PD-L1 and PD-1 was significantly higher in OSCC with OSF than OSCC without OSF tissues (p = 0.0043 and, p = 0.0012, respectively). CONCLUSIONS The present study suggested that PD-L1 may be an unfavorable indicator for prognosis. PD-L1/PD-1 signaling might play an important role in the malignant transformation of OSF, and targeting PD-L1/PD-1 signaling may be a new therapeutic strategy for OSCC, especially in OSCC patients with OSF.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D009914 Oral Submucous Fibrosis Irreversible FIBROSIS of the submucosal tissue of the MOUTH. Fibroses, Oral Submucous,Fibrosis, Oral Submucous,Oral Submucous Fibroses,Submucous Fibroses, Oral,Submucous Fibrosis, Oral
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D060890 B7-H1 Antigen An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION. Antigens, CD274,PD-L1 Protein,Programmed Cell Death 1 Ligand 1 Protein,Programmed Death Ligand 1,B7-H1 Immune Costimulatory Protein,B7H1 Immune Costimulatory Protein,CD274 Antigen,PD-L1 Costimulatory Protein,Programmed Cell Death 1 Ligand 1,Antigen, B7-H1,Antigen, CD274,B7 H1 Antigen,B7 H1 Immune Costimulatory Protein,CD274 Antigens,Costimulatory Protein, PD-L1,PD L1 Costimulatory Protein,PD L1 Protein
D061026 Programmed Cell Death 1 Receptor An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE. PD-1 Protein,Programmed Cell Death 1 Protein,Programmed Cell Death Protein 1,Antigens, CD279,CD279 Antigen,PD-1 Receptor,PD1 Receptor,Antigen, CD279,CD279 Antigens,PD 1 Protein,PD 1 Receptor,Receptor, PD-1,Receptor, PD1

Related Publications

Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
January 2020, Open medicine (Warsaw, Poland),
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
August 2020, Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology,
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
October 2016, World journal of gastroenterology,
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
October 2016, Pathology,
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
May 2016, Oncotarget,
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
February 2024, Oncology letters,
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
January 2022, Open medicine (Warsaw, Poland),
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
October 2015, Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology,
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
July 2020, The Journal of surgical research,
Hongzhi Quan, and Sixuan Liu, and Zhongyan Shan, and Ziyi Liu, and Tianjun Chen, and Yanjia Hu, and Zhigang Yao, and Liangjuan Fang
January 2018, Indian journal of dental research : official publication of Indian Society for Dental Research,
Copied contents to your clipboard!